BIO VentureForum East 2007

18-20 June 2007 / Marriott Chateau Champlain / Montreal / Quebec / Canada

The Biotechnology Industry Organization (BIO), in partnership with 14 state biotechnology associations and BIOTECanada will bring venture capitalists together with promising seed, early- and late-stage private biotechnology product and platform companies from the East Coast. The conference will showcase up to 100 individual company presentations to leading North American venture capital firms in the life sciences field. Workshops and plenary sessions will be offered on trends in the biotech industry, with special focus on key success factors for early-stage companies, R&D, market trends, and financing. In addition, there will be formal and informal networking opportunities with industry CEOs and venture capital leaders.

To ensure high quality deal flow, an advisory board made up of 30 equity capital leaders will review and evaluate the corporate profiles of companies through an application process. Selected entrepreneurs will also attend regional BIO VentureForum Bootcamps to be intensively coached and provided with the tools needed to refine their presentations and grow their enterprises.

Who Should Attend:

• Venture capital investors
• Institutional investors
• CEOs and other senior pharmaceutical and biotechnology industry executives
• Tech transfer managers at research universities and principal investigators moving toward product commercialization
• Other professionals and experts who support the biotechnology industry

Why Present?

“Protez Pharmaceuticals attendance at BIO Venture Forum East 2005 conference was helpful in finalizing our venture syndicate which resulted in a $15 million round of financing for the company.” -- Chris Cashman, President and CEO of Protez Pharmaceuticals.

"Our presentation and the networking opportunities that were provided to us at BIO Venture Forum East 2005 enabled us to communicate our story to a large group of new investors which contributed to the successful financing that is now fueling clinical development of our Alzheimer's disease imaging agents." --Dr. Daniel Skovronsky, President and CEO of Avid Radiopharmaceuticals.

Read more about the event click here.

Registration click here.  

Programme click here.